Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years

Figure 3 Changes in mean scores of aspartate aminotransferase to platelet ratio index, fibrosis-4, and shear wave elastography reading after tenofovir disoproxil fumarate switching to tenofovir alafenamide, compared to baseline. A-C: The changes in mean score of aspartate aminotransferase to platelet ratio index (APRI) (A), fibrosis-4 (FIB-4) (B), and shear wave elastography (SWE) reading (C) with standard deviations are shown on the y-axis. The time course of switching is shown on the x-axis. There was a great reduction in the mean scores for both APRI (A), FIB-4 (B) scores at switching week 144 and SWE reading (C) at a mean of 109 weeks switching from tenofovir disoproxil fumarate to tenofovir alafenamide (P < 0.001). FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase to platelet ratio index; SWE: Shear wave elastography.